StockSelector.com
  Research, Select, & Monitor Tuesday, November 20, 2018 8:23:42 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Alexion Pharmaceuticals, Inc.$116.82$1.761.53%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Alexion Pharmaceuticals, Inc. vs Drug Manufacturers/Other

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.




Engaged in the discovery, development, and commercialization of innovative pharmaceuticals for the treatment of many diseases, either directly or indirectly. Directly treating a disease would involve some sort of drug that could attack the infection itself. An indirect treatment may involve a drug that's used to enhance the body's own antibody production so those antibodies can attack the infection themselves. Not only do some of these companies develop drugs for human use, a good number of them also work on animal or plant diseases as well.
 Totals Company Industry
  Sales: $3,551.1 Mil $103,380.7 Mil
  Market Cap: $25,842.5 Mil $351,863.7 Mil
  Analysts Recommendation: Strong Buy Buy

 Averages Company Industry
 Growth
  Historic Revenue: 15.1% 46.3%
  Estimated Revenue: 14.6% 22.6%
  Historic Earnings: 36.5% (63.9%)
  Estimated Earnings: N/A 17.6%
  Stock Price (1 Year): 3.8% (.6%)
  Cash per Share: (39.4%) 25.7%
  Dividend: N/A N/A
 Price
  Trailing PE: N/A N/A
  Forward PE: .1 32.3
  Price-to-Sales: 6.6 N/A
  Price-to-Book: 2.9 5.6
  Dividend Yield: N/A N/A
  Market Cap: $25,842.5 Mil $12,133.2 Mil
  Operations
  Net Margin: 38.1% (240.3%)
  Gross Margin: 87.2% 83.3%
  Return on Equity: .0 (1.5)
  Return on Assets: .0 (.2)
  Balance Sheet
  Current Ratio: 3.1 5.5
  Quick Ratio: 2.6 5.3
  Cash Ratio: 1.5 4.7
  Debt-to-Equity: .5 2.8
  Interest Coverage: .2 .7
 Technicals
  Relative-Strength Index: 39.7 N/A

 Other companies in Drug Manufacturers/Other Price Market Cap
  Novo Nordisk A\/S  (NVO) $45.47 $110,001.0 Mil
  UBS AG  (UBS) $13.65 $53,149.7 Mil
  Allergan plc  (AGN) $156.04 $52,897.6 Mil
  Vertex Pharmaceuticals Inc.  (VRTX) $161.07 $41,844.1 Mil
  Teva Pharmaceutical Industries, Ltd  (TEVA) $22.00 $22,396.0 Mil






Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.